NYSE:PBH Prestige Consumer Healthcare - PBH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prestige Consumer Healthcare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $61.49 -1.17 (-1.87%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$61.25▼$62.7350-Day Range$58.41▼$67.0552-Week Range$48.51▼$67.45Volume213,509 shsAverage Volume286,702 shsMarket Capitalization$3.06 billionP/E Ratio14.75Dividend YieldN/APrice Target$77.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Prestige Consumer Healthcare MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside25.9% Upside$77.40 Price TargetShort InterestBearish2.23% of Float Sold ShortDividend StrengthN/ASustainability-2.35Upright™ Environmental ScoreNews Sentiment0.82Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth4.31%From $4.18 to $4.36 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsConsumer Discretionary Sector202nd out of 262 stocksPharmaceutical Preparations Industry332nd out of 489 stocks 3.3 Analyst's Opinion Consensus RatingPrestige Consumer Healthcare has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $77.40, Prestige Consumer Healthcare has a forecasted upside of 25.9% from its current price of $61.49.Amount of Analyst CoveragePrestige Consumer Healthcare has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.23% of the float of Prestige Consumer Healthcare has been sold short.Short Interest Ratio / Days to CoverPrestige Consumer Healthcare has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Prestige Consumer Healthcare has recently increased by 20.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrestige Consumer Healthcare does not currently pay a dividend.Dividend GrowthPrestige Consumer Healthcare does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrestige Consumer Healthcare has received a 42.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Dental floss", "Topical capsaicin", "Mouthwash", "Lice shampoo", "Montelukast", and "Yeast infection medicine" products. See details.Environmental SustainabilityThe Environmental Impact score for Prestige Consumer Healthcare is -2.35. Previous Next 2.7 News and Social Media Coverage News SentimentPrestige Consumer Healthcare has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Consumer Discretionary companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Prestige Consumer Healthcare this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prestige Consumer Healthcare insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of Prestige Consumer Healthcare is held by insiders.Percentage Held by Institutions99.98% of the stock of Prestige Consumer Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Prestige Consumer Healthcare are expected to grow by 4.31% in the coming year, from $4.18 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prestige Consumer Healthcare is 14.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Prestige Consumer Healthcare is 14.75, which means that it is trading at a more expensive P/E ratio than the Consumer Discretionary sector average P/E ratio of about 14.39.Price to Earnings Growth RatioPrestige Consumer Healthcare has a PEG Ratio of 1.86. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPrestige Consumer Healthcare has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prestige Consumer Healthcare (NYSE:PBH) StockPrestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.Read More Receive PBH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter. Email Address PBH Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comBrokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $77.40March 20, 2023 | finance.yahoo.comPrestige Consumer Healthcare Inc. (PBH)March 29, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 20, 2023 | americanbankingnews.comRoyal Bank of Canada Cuts Prestige Consumer Healthcare (NYSE:PBH) Price Target to $104.00March 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lifecore Biomedical (LFCR), Prestige Consumer Healthcare (PBH) and Quest Diagnostics (DGX)February 25, 2023 | finance.yahoo.comPrestige Consumer Healthcare Inc.'s (NYSE:PBH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?February 2, 2023 | finance.yahoo.comPrestige Consumer Healthcare Inc. Reports Third Quarter ResultsFebruary 2, 2023 | finance.yahoo.comPrestige Brands (PBH) Q3 Earnings and Revenues Surpass EstimatesMarch 29, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.January 27, 2023 | nasdaq.comPrestige Consumer (PBH) to Post Q3 Earnings: Factors to ConsiderJanuary 19, 2023 | seekingalpha.comPrestige Consumer Healthcare: Taking My Winnings Off The TableJanuary 9, 2023 | finance.yahoo.comPrestige Consumer Healthcare Inc. to Present at the 2023 ICR ConferenceJanuary 5, 2023 | finance.yahoo.comPrestige Consumer Healthcare Inc. to Release Fiscal 2023 Third Quarter Earnings ResultsDecember 12, 2022 | finance.yahoo.comInvesting in Prestige Consumer Healthcare (NYSE:PBH) three years ago would have delivered you a 53% gainDecember 1, 2022 | msn.comImplied Volatility Surging for Prestige (PBH) Stock OptionsNovember 26, 2022 | finance.yahoo.comAn Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% UndervaluedNovember 9, 2022 | finance.yahoo.comPrestige Consumer Healthcare Second Quarter 2023 Earnings: Beats ExpectationsNovember 6, 2022 | seekingalpha.comPrestige Consumer Healthcare Inc. (PBH) Q2 2023 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comPrestige Brands (PBH) Tops Q2 Earnings and Revenue EstimatesNovember 3, 2022 | finance.yahoo.comPrestige Consumer Healthcare Inc. Reports Second Quarter Results and Reaffirms Outlook for Fiscal 2023October 27, 2022 | finance.yahoo.comEarnings Preview: Prestige Brands (PBH) Q2 Earnings Expected to DeclineOctober 10, 2022 | nasdaq.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?October 4, 2022 | finance.yahoo.comPrestige Consumer Healthcare Inc. to Release Fiscal 2023 Second Quarter Earnings ResultsSeptember 28, 2022 | nasdaq.comHere's Why Prestige Brands (PBH) is a Strong Value StockSeptember 22, 2022 | nasdaq.comPrestige Consumer Healthcare Inc Shares Near 52-Week Low - Market MoverSeptember 18, 2022 | finance.yahoo.comDeclining Stock and Decent Financials: Is The Market Wrong About Prestige Consumer Healthcare Inc. (NYSE:PBH)?September 17, 2022 | nasdaq.comPrestige Consumer Healthcare Inc Shares Close in on 52-Week Low - Market MoverSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PBH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter. Email Address PBH Company Calendar Last Earnings2/02/2023Today3/29/2023Fiscal Year End3/31/2023Next Earnings (Estimated)5/04/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryPersonal Products SectorConsumer Discretionary Current SymbolNYSE:PBH CUSIP74112D10 CIK1295947 Webwww.prestigebrands.com Phone(914) 524-6800Fax302-674-5266Employees505Year FoundedN/APrice Target and Rating Average Stock Price Forecast$77.40 High Stock Price Forecast$104.00 Low Stock Price Forecast$70.00 Forecasted Upside/Downside+25.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$4.17 Trailing P/E Ratio14.75 Forward P/E Ratio14.71 P/E Growth1.86Net Income$205.38 million Net Margins18.97% Pretax Margin24.04% Return on Equity12.65% Return on Assets5.54% Debt Debt-to-Equity Ratio0.85 Current Ratio2.55 Quick Ratio1.56 Sales & Book Value Annual Sales$1.09 billion Price / Sales2.81 Cash Flow$4.77 per share Price / Cash Flow12.89 Book Value$31.43 per share Price / Book1.96Miscellaneous Outstanding Shares49,690,000Free Float48,893,000Market Cap$3.06 billion OptionableOptionable Beta0.56 Key ExecutivesRonald M. LombardiChairman, President & Chief Executive OfficerJeff ZerilloSenior Vice President-OperationsChristine SaccoChief Financial OfficerWilliam C. P'PoolSecretary, Senior Vice President & General CounselAdel MekhailExecutive Vice President-Marketing & SalesKey CompetitorsPowerSchoolNYSE:PWSCTravel + LeisureNYSE:TNLPeloton InteractiveNASDAQ:PTONAcushnetNYSE:GOLFGrahamNYSE:GHCView All CompetitorsInstitutional OwnershipMetLife Investment Management LLCSold 685 shares on 3/23/2023Ownership: 0.052%Victory Capital Management Inc.Bought 38,341 shares on 3/10/2023Ownership: 0.987%North Star Asset Management Inc.Sold 1,810 shares on 3/6/2023Ownership: 0.495%Rockefeller Capital Management L.P.Bought 524 shares on 3/6/2023Ownership: 0.002%Voya Investment Management LLCSold 7,386 shares on 2/28/2023Ownership: 0.081%View All Institutional Transactions PBH Stock - Frequently Asked Questions Should I buy or sell Prestige Consumer Healthcare stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBH shares. View PBH analyst ratings or view top-rated stocks. What is Prestige Consumer Healthcare's stock price forecast for 2023? 6 brokerages have issued 1-year price targets for Prestige Consumer Healthcare's shares. Their PBH share price forecasts range from $70.00 to $104.00. On average, they expect the company's stock price to reach $77.40 in the next twelve months. This suggests a possible upside of 25.9% from the stock's current price. View analysts price targets for PBH or view top-rated stocks among Wall Street analysts. How have PBH shares performed in 2023? Prestige Consumer Healthcare's stock was trading at $62.60 at the beginning of 2023. Since then, PBH shares have decreased by 1.8% and is now trading at $61.49. View the best growth stocks for 2023 here. Are investors shorting Prestige Consumer Healthcare? Prestige Consumer Healthcare saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,100,000 shares, an increase of 20.2% from the February 28th total of 914,900 shares. Based on an average daily volume of 276,400 shares, the short-interest ratio is presently 4.0 days. Currently, 2.2% of the company's stock are short sold. View Prestige Consumer Healthcare's Short Interest. When is Prestige Consumer Healthcare's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our PBH earnings forecast. How were Prestige Consumer Healthcare's earnings last quarter? Prestige Consumer Healthcare Inc. (NYSE:PBH) posted its quarterly earnings data on Thursday, February, 2nd. The company reported $1.04 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.03. The business had revenue of $275.50 million for the quarter, compared to analysts' expectations of $273.84 million. Prestige Consumer Healthcare had a net margin of 18.97% and a trailing twelve-month return on equity of 12.65%. The business's revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.99 EPS. What ETFs hold Prestige Consumer Healthcare's stock? ETFs with the largest weight of Prestige Consumer Healthcare (NYSE:PBH) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco Dynamic Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Schwab Ariel ESG ETF (SAEF), SPDR S&P Pharmaceuticals ETF (XPH), Global X Health & Wellness ETF (BFIT), iShares U.S. Pharmaceuticals ETF (IHE) and ETC 6 Meridian Small Cap Equity ETF (SIXS). What guidance has Prestige Consumer Healthcare issued on next quarter's earnings? Prestige Consumer Healthcare updated its FY 2023 earnings guidance on Thursday, February, 2nd. The company provided EPS guidance of $4.18-$4.18 for the period, compared to the consensus earnings per share estimate of $4.20. The company issued revenue guidance of $1.12 billion-$1.12 billion, compared to the consensus revenue estimate of $1.12 billion. What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO? 8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Prestige Consumer Healthcare own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA). What is Prestige Consumer Healthcare's stock symbol? Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH." Who are Prestige Consumer Healthcare's major shareholders? Prestige Consumer Healthcare's stock is owned by a variety of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (7.40%), Macquarie Group Ltd. (3.97%), Allspring Global Investments Holdings LLC (2.14%), Nordea Investment Management AB (2.07%), Geode Capital Management LLC (1.84%) and LSV Asset Management (1.74%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi. View institutional ownership trends. How do I buy shares of Prestige Consumer Healthcare? Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prestige Consumer Healthcare's stock price today? One share of PBH stock can currently be purchased for approximately $61.49. How much money does Prestige Consumer Healthcare make? Prestige Consumer Healthcare (NYSE:PBH) has a market capitalization of $3.06 billion and generates $1.09 billion in revenue each year. The company earns $205.38 million in net income (profit) each year or $4.17 on an earnings per share basis. How many employees does Prestige Consumer Healthcare have? The company employs 505 workers across the globe. How can I contact Prestige Consumer Healthcare? Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The official website for the company is www.prestigebrands.com. The company can be reached via phone at (914) 524-6800, via email at irinquiries@prestigebrands.com, or via fax at 302-674-5266. This page (NYSE:PBH) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.